Amato Paula, Mikhalchenko Aleksei, Mitalipov Shoukhrat
Division of Reproductive Endocrinology, Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon; Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University, Portland, Oregon.
Division of Reproductive Endocrinology, Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon.
Fertil Steril. 2025 May 5. doi: 10.1016/j.fertnstert.2025.04.039.
Germline gene editing refers to altering the DNA in the reproductive cells (gametes or embryos). Germline gene editing experiments in human embryos have primarily focused on correcting genetic mutations linked to inherited diseases. This technology has the potential to prevent genetic disease before birth and in future generations. Advances in CRISPR-Cas9 and other gene-editing tools have accelerated scientific progress, raising both promise and safety and ethical concerns. A translational pathway for human heritable genome editing will require an approach that integrates scientific validation, ethical oversight, regulatory frameworks, and public engagement.
生殖系基因编辑是指改变生殖细胞(配子或胚胎)中的DNA。对人类胚胎进行的生殖系基因编辑实验主要集中在纠正与遗传疾病相关的基因突变。这项技术有潜力在出生前和后代中预防遗传疾病。CRISPR-Cas9及其他基因编辑工具的进展加速了科学进步,带来了希望,同时也引发了安全和伦理方面的担忧。人类可遗传基因组编辑的转化途径将需要一种整合科学验证、伦理监督、监管框架和公众参与的方法。